Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The President and Plan B

This article was originally published in The Tan Sheet

Executive Summary

President Bush's sentiments about birth control are "directly at odds with FDA's extraordinary refusal to approve OTC sale of emergency contraception products," according to letter to the President sent by the Center for Reproductive Rights July 6. The letter refers to a recent statement by the Bush administration that the President supports the "availability of safe and effective products and services to assist responsible adults in making decisions about preventing or delaying conception." The administration's position on birth control was requested by Members of Congress in July 2005. The reasons for delaying an answer to Barr Labs' Plan B switch application "appear to have nothing to do with the safety or effectiveness of Plan B - the only considerations that are the proper purview of the FDA," CRR maintains. "If the administration indeed supports safe and effective products and services to assist responsible adults...then there is no reason for its failure to support the availability of EC"...

You may also be interested in...

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts